Paliperidone supplier | CasNO.144598-75-4

Name
Paliperidone
EINECS 620-493-1
CAS No. 144598-75-4
Article Data57
CAS DataBase
Density 1.45 g/cm³
Solubility
Melting Point 158-160 °C
Formula C₂₃H₂₇FN₄O₃
Boiling Point 612.3 °C at 760 mmHg
Molecular Weight 426.491
Flash Point 324.1 °C
Transport Information UN 2811 6.1/PG 3
Appearance off white to light orange coloured solid
Safety 45
Risk Codes 25
Molecular Structure
Hazard Symbols T
Synonyms 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4- (6-fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]ethyl]-6,7,8,9-tetrahydro-9- hydroxy-2-methyl-;9-Hydroxyrisperidone;
PSA 84.39000
LogP 3.01920

Paliperidone Chemical Properties

Product Name: Paliperidone (CAS NO.144598-75-4)

Molecular Formula: C₂₃H₂₇FN₄O₃
Molecular Weight: 426.48g/mol
Mol File: 144598-75-4.mol
Appearance: Off White to Light Orange Coloured Solid
Melting Point: 158-160°C
Boiling point: 612.32 °C at 760 mmHg
Storage Temperature: Room temp
Flash Point: 324.12 °C
Density: 1.45 g/cm³
Surface Tension: 54.583 dyne/cm
Enthalpy of Vaporization: 95.571 kJ/mol
XLogP3-AA: 2.2
H-Bond Donor: 1
H-Bond Acceptor: 7
Structure Descriptors of Paliperidone (CAS NO.144598-75-4):
IUPAC Name: (9R)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Canonical SMILES: CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
Isomeric SMILES: CC1=C(C(=O)N2CCC[C@H](C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
InChI: InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3/t19-/m1/s1
InChIKey: PMXMIIMHBWHSKN-LJQANCHMSA-N
Product Categories: Various Metabolites and Impurities; Intermediates & Fine Chemicals; Metabolites & Impurities; Pharmaceuticals

Paliperidone History

Paliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone (as Invega) was approved by the FDA for the treatment of schizophrenia on December 20, 2006.

Paliperidone Uses

It is indicated for the acute and maintenance treatment of schizophrenia. The drug significantly reduces side-effects present in other anti-psychotic drugs formerly used to treat schizophrenia and bipolar disorder. In short-term studies paliperidone has been shown to be effective, demonstrating improvements in symptom scores, compared with placebo.

Paliperidone Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
rat	LD50	oral	65mg/kg (65mg/kg)		Drug Development Research. Vol. 33, Pg. 399, 1994.

Paliperidone Safety Profile

Safety Information of Paliperidone (CAS NO.144598-75-4):
Hazard Codes: T Toxic
Risk Statements: 25
R25 :Toxic if swallowed.
Safety Statements: 45
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: UN 2811 6.1/PG 3
RTECS: UV1164720

Paliperidone Specification

Paliperidone , its CAS NO. is 144598-75-4, the synonyms are (9RS)-3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-
yl))ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido(1,2-a)pyrimidin-4-one ; 4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl- ; 9-Hydroxyrisperidone ; Invega ; Paliperidone ; RO76477 ; UNII-838F01T721 .

Product Name

Paliperidone